The Ministry of Health announced, this Friday (21), the inclusion in the PNO (National Vaccination Operational Plan) of the CoronaVac Covid-19 vaccine for children and adolescents aged 6 to 17 years. The announcement was made by the executive secretary of the portfolio, Rodrigo Cruz.
Cruz informed that the folder will forward a letter to the states to find out how many doses of the immunizer they have and if they need to receive more units. According to the technician, there are about three million doses in possession of the states — the Federal District, for example, has 500,000 in stock.
read more:
Rodrigo Cruz highlighted, however, that he has already identified at least 12 states that do not have doses of CoronaVac. A meeting is expected to be held in the coming days to resolve the impasse.
The Ministry of Health also stated that it has six million doses of the immunizing agent available at the Distribution Center for Strategic Health Supplies, in Guarulhos (SP). Cruz reported that the number of doses of the vaccine that the Union will buy from Butantan has not yet been defined, but the ministry is negotiating the purchase of more than 7 million units.
The measure takes place one day after Anvisa (National Health Surveillance Agency) approves the use of the immunizing agent for this age group. The request from the Butantan Institute requested use from the age of 3, but the regulator limited the extension based on the preliminary results of the clinical studies presented to guide the authorization.
The decision was unanimous, taken by the agency’s collegiate board, since the vaccine does not have a definitive record, and it is up to the directors to deliberate on the subject. Anvisa’s indication provides that the dose for children is the same as for adults. The interval between applications should be between two and four weeks.
The authorization comes just over a month after the second request, made on December 15, 2021 by the Butantan Institute, responsible for CoronaVac in Brazil. The first process was filed in July 2021 and, in August, the agency decided not to approve the extension of the vaccine’s use, considering that, at the time, there was not enough data to support the regulatory approval.
The ministry already uses Pfizer’s Covid-19 vaccine for the immunization of children aged 5 to 11 years, with pediatric doses, and 12 to 17 years with the normal dose, for adults. So far, the country has received about 2.5 million pediatric doses of the American pharmaceutical and the forecast is that a new batch, with 1.8 million doses, will arrive in the country next Monday (24).
The Ministry of Health announced, this Friday (21), the inclusion in the PNO (National Vaccination Operational Plan) of the CoronaVac Covid-19 vaccine for children and adolescents aged 6 to 17 years. The announcement was made by the executive secretary of the portfolio, Rodrigo Cruz.
Cruz informed that the folder will forward a letter to the states to find out how many doses of the immunizer they have and if they need to receive more units. According to the technician, there are about three million doses in possession of the states — the Federal District, for example, has 500,000 in stock.
read more:
Rodrigo Cruz highlighted, however, that he has already identified at least 12 states that do not have doses of CoronaVac. A meeting is expected to be held in the coming days to resolve the impasse.
The Ministry of Health also stated that it has six million doses of the immunizing agent available at the Distribution Center for Strategic Health Supplies, in Guarulhos (SP). Cruz reported that the number of doses of the vaccine that the Union will buy from Butantan has not yet been defined, but the ministry is negotiating the purchase of more than 7 million units.
The measure takes place one day after Anvisa (National Health Surveillance Agency) approves the use of the immunizing agent for this age group. The request from the Butantan Institute requested use from the age of 3, but the regulator limited the extension based on the preliminary results of the clinical studies presented to guide the authorization.
The decision was unanimous, taken by the agency’s collegiate board, since the vaccine does not have a definitive record, and it is up to the directors to deliberate on the subject. Anvisa’s indication provides that the dose for children is the same as for adults. The interval between applications should be between two and four weeks.
The authorization comes just over a month after the second request, made on December 15, 2021 by the Butantan Institute, responsible for CoronaVac in Brazil. The first process was filed in July 2021 and, in August, the agency decided not to approve the extension of the vaccine’s use, considering that, at the time, there was not enough data to support the regulatory approval.
The ministry already uses Pfizer’s Covid-19 vaccine for the immunization of children aged 5 to 11 years, with pediatric doses, and 12 to 17 years with the normal dose, for adults. So far, the country has received about 2.5 million pediatric doses of the American pharmaceutical and the forecast is that a new batch, with 1.8 million doses, will arrive in the country next Monday (24).
